Weijin Fu, Zhibin Xie, Shengfeng Zheng, Xiaoli Yang, Qijian Ding, Jiayi Liu, Qiumei Liang, Yilong Chen, Hua Mi, Deyun Liu, Jiwen Cheng
Department of Urology, The First Affiliated Hospital of GuangXi Medical University, NanNing.
Scientific Research Center, GuiLin Medical University, GuiLin.
Medicine (Baltimore). 2019 Jul;98(28):e16384. doi: 10.1097/MD.0000000000016384.
Pyrroline-5-carboxylate reductase 1 (PYCR1) is an enzyme involved in cell metabolism and is upregulated in cancer. However, the correlations of PYCR1 expression with the clinicopathological features and prognosis of renal cell carcinoma (RCC) remain unclear. The purpose of this study was to identify the expression of PYCR1 and its clinical relevance in RCC patients.PYCR1 mRNA expression differences between RCC and the adjacent normal renal tissues were assessed using the Cancer Genome Atlas database (TCGA). Subsequently, the expression of PYCR1 mRNA and protein were evaluated by quantitative real-time polymerase chain reaction, Western blot, and immunochemistry using 30 paired frozen samples of RCC and the adjacent normal renal tissues. The protein expression of PYCR1 was evaluated by immunostaining formalin-fixed, paraffin-embedded sections of RCC samples from 96 patients who underwent radical nephrectomy, and its relationship with clinical features were analyzed. Nonpaired t tests were used to statistically analyze the differences between the 2 groups. Cox univariable and multivariable analyses of overall survival (OS) among RCC patients were performed.The expression of PYCR1 mRNA was significantly upregulated in RCC tissues compared to adjacent normal renal tissues in the TCGA database (P < .01). The area under the receiver operating characteristic curve value was 0.748. The expression of PYCR1 mRNA and protein was significantly upregulated in RCC compared with that in paired normal renal tissues (P < .01). Higher PYCR1 levels were associated with metastasis (P < .01). Kaplan-Meier survival curves indicated that higher PYCR1 expression was correlated with poorer OS. Therefore, PYCR1 may act as a novel prognostic marker and therapeutic target in the diagnosis and treatment of RCC.
吡咯啉-5-羧酸还原酶1（PYCR1）是一种参与细胞代谢的酶，在癌症中表达上调。然而，PYCR1表达与肾细胞癌（RCC）临床病理特征及预后的相关性仍不清楚。本研究旨在确定RCC患者中PYCR1的表达及其临床相关性。利用癌症基因组图谱数据库（TCGA）评估RCC与相邻正常肾组织之间PYCR1 mRNA表达差异。随后，使用30对RCC和相邻正常肾组织的冷冻样本，通过定量实时聚合酶链反应、蛋白质免疫印迹和免疫化学评估PYCR1 mRNA和蛋白质的表达。通过对96例行根治性肾切除术患者的RCC样本福尔马林固定、石蜡包埋切片进行免疫染色来评估PYCR1的蛋白表达，并分析其与临床特征的关系。采用非配对t检验对两组之间的差异进行统计学分析。对RCC患者的总生存期（OS）进行Cox单因素和多因素分析。在TCGA数据库中，与相邻正常肾组织相比，RCC组织中PYCR1 mRNA表达显著上调（P<0.01）。受试者工作特征曲线下面积值为0.748。与配对的正常肾组织相比，RCC中PYCR1 mRNA和蛋白质表达显著上调（P<0.01）。较高的PYCR1水平与转移相关（P<0.01）。Kaplan-Meier生存曲线表明，较高的PYCR1表达与较差的OS相关。因此，PYCR1可能作为RCC诊断和治疗中的一种新型预后标志物和治疗靶点。
Zotero 插件
